Keros Therapeutics, Inc. $KROS Stock Position Lowered by SG Americas Securities LLC

Posted by Geri Gentry on Jul 14th, 2026

SG Americas Securities LLC decreased its position in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) by 90.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,135 shares of the company’s stock after selling 89,568 shares during the quarter. SG Americas Securities LLC’s holdings in Keros Therapeutics were worth $101,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of KROS. The Manufacturers Life Insurance Company raised its position in Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after acquiring an additional 988 shares in the last quarter. UBS Group AG boosted its position in shares of Keros Therapeutics by 1.1% during the 3rd quarter. UBS Group AG now owns 103,864 shares of the company’s stock valued at $1,643,000 after purchasing an additional 1,091 shares in the last quarter. Strs Ohio boosted its position in shares of Keros Therapeutics by 3.9% during the 4th quarter. Strs Ohio now owns 29,300 shares of the company’s stock valued at $597,000 after purchasing an additional 1,100 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares during the last quarter. Finally, Financial Management Professionals Inc. bought a new stake in shares of Keros Therapeutics in the 4th quarter worth approximately $29,000. Institutional investors own 71.56% of the company’s stock.

Analyst Ratings Changes

KROS has been the subject of several recent research reports. Wall Street Zen lowered shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.40.

Get Our Latest Stock Report on KROS

Insider Activity

In other news, Director Julius Knowles sold 2,625 shares of Keros Therapeutics stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director owned 10,958 shares in the company, valued at approximately $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the transaction, the director directly owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,425 shares of company stock worth $89,994 over the last quarter. Corporate insiders own 12.60% of the company’s stock.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $11.10 on Tuesday. Keros Therapeutics, Inc. has a fifty-two week low of $9.69 and a fifty-two week high of $22.55. The firm’s 50 day simple moving average is $10.96 and its 200-day simple moving average is $13.58. The company has a market cap of $219.67 million, a P/E ratio of -3.69 and a beta of 0.97.

Keros Therapeutics (NASDAQ:KROS – Get Free Report) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The firm had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. On average, analysts expect that Keros Therapeutics, Inc. will post -5.19 EPS for the current fiscal year.

About Keros Therapeutics

(Free Report)

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.